SpaceX’s public float is only a small fraction of the company, and Elon Musk will not be allowed to sell his shares until an extended lockup expires next June.
Electric vehicle battery manufacturer QuantumScape endured a difficult start to trading in 2021, with its stock falling by an astronomical 41% on January 4th. Several reasons have been given for this steep decline, ranging from the company’s filing known as a Resale S-1 form on December 31st to the...
Fletcher Building increased its fiscal 2026 continuing operations EBIT outlook, helped by surplus property sales, while warning that inflation and macro uncertainty could weigh on results next year.
Artificial intelligence shares have beaten the broader market this year, and the report highlights Nvidia and Celestica as two AI infrastructure names that could benefit further from continued spending.
Biotech company Moderna experienced a 15% drop in the last three days, its lowest value for the month of December. Since posting its all-time high stock price on December 1st, Moderna shares have declined by a margin of 30%.
This decline looks to be the result of sales spurred by...
Gloo Holdings priced its underwritten public offering of 7 million Class A shares at $3.25 apiece, with the deal expected to close July 10.
With concerns over potential pandemic shutdowns now overshadowing the promising news surrounding COVID-19 vaccine developments, U.S. stocks have experienced significant losses after a late-session sell-off on Wednesday.
Throughout Wednesday’s trading, all three major U.S. stock indexes fluctuated widely. Inverness Counsel chief investment strategist Tim Ghriskey explained that the reason for...
Following reports of the New York Stock Exchange deciding to remove the three largest Chinese telecom companies, Chinese oil companies look to be the next in line to be delisted. The company that’s most in the hot seat is CNOOC Ltd—and they also happen to be the biggest offshore...
Johnson & Johnson stocks slid by 0.2% during afternoon trading on Wednesday after reports of its coronavirus vaccine candidate falling two months behind schedule.
While the pharmaceutical company had initially planned to have 12 million doses of its vaccine ready for distribution by the end of February, several delays have...
Food delivery company DoorDash debuted on the NYSE last week and unfortunately suffered a rough decline right afterward. This wasn’t helped by Citron Research, who referred to their initial public offering as the “most ridiculous” one that year. Citron also believed that they had immensely overvalued themselves.
According to Citron,...